SCHEMBL16790045

SCHEMBL16790045

COc1cncc2nnc(C(F)(F)F)n12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 7/20 0.39
PDE2A O00408 5/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
CYP1A2 P05177 5/20 0.33
ALDH1A1 P00352 1/20 0.33
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
JAK2 O60674 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
MET P08581 1/20 0.32
PDGFRB P09619 1/20 0.32
FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5935860 0.79 ALDH1A1 (0.36) SCN5APDE2ASCN1ASCN2ACYP1A2
SCHEMBL9040622 0.57 ALDH1A1 (0.36) PDE2ACYP1A2ALDH1A1HPGDCYP2C19
SCHEMBL31569041 0.56 SCN5A (0.35) SCN5A
SCHEMBL5652378 0.55 CYP1A2 (0.56) SCN5ASCN1ASCN2ACYP1A2ALDH1A1
SCHEMBL1665000 0.55 CYP1A2 (0.44) SCN5AL3MBTL1CYP1A2ALDH1A1HPGD
SCHEMBL12909225 0.55 ALDH1A1 (0.44) SCN5ASCN1ASCN2ACYP1A2ALDH1A1
SCHEMBL16363146 0.55 MAPT (0.42) SCN5ACYP1A2ALDH1A1NPSR1
SCHEMBL11773952 0.54 SMN1; SMN2 (0.57) L3MBTL1CYP1A2ALDH1A1HPGDNPSR1
SCHEMBL21721462 0.53 TDP1 (0.32)
SCHEMBL12911394 0.53 ALDH1A1 (0.64) SCN5AL3MBTL1CYP1A2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255106-B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2016-02-09 US disclosed
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) 2015-06-18 US disclosed
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) 2015-06-18 US disclosed
EP-2881395-A1 PIPERAZINOTRIZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2015-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166544-A1 PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION PARP1, PARP11, PARP8 SCN5A 2030/4885PDE2A 2557/4885L3MBTL1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.